As a point of fact, therapeutic utilization of the pharmacological agonists of PPAR-α and PPAR-γ showed promising results in reducing IR and inflammation and interrupting the pathogenesis of DM and NAFLD in animal models and human patients [14–17]. Here, PPARG is linked to metabolic dysfunction-associated steatotic liver disease.